Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | HSP90AA1 | P07900 | 3/20 | 0.48 |
| ▸ | HTT | P42858 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | MMP2 | P08253 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 2/20 | 0.48 |
| ▸ | CCR1 | P32246 | 2/20 | 0.48 |
| ▸ | CCR5 | P51681 | 2/20 | 0.48 |
| ▸ | CCR8 | P51685 | 2/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | GMNN | O75496 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | MMP9 | P14780 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.48 |
| ▸ | MMP8 | P22894 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31509775 | 1.00 | LMNA (0.48) | LMNAKDM4ESMN1; SMN2HSP90AA1HTT | |
| Ethoxycarbonyl Group SCHEMBL27838242 | 0.81 | LMNA (0.36) | LMNAKDM4ESMN1; SMN2HSP90AA1HTT | |
| SCHEMBL196509 | 0.78 | LMNA (0.64) | LMNAKDM4ESMN1; SMN2HSP90AA1HTT | |
| Water SCHEMBL28285432 | 0.76 | LMNA (0.61) | LMNAKDM4ESMN1; SMN2HSP90AA1HTT | |
| SCHEMBL277027 | 0.75 | MMP2 (0.61) | LMNAKDM4ESMN1; SMN2HSP90AA1HTT | |
| SCHEMBL20172096 | 0.75 | PSMD14 (0.61) | LMNAKDM4ESMN1; SMN2HSP90AA1HTT | |
| SCHEMBL20172095 | 0.75 | HSP90AA1 (0.48) | LMNAKDM4ESMN1; SMN2HSP90AA1HTT | |
| SCHEMBL10134475 | 0.75 | CCR1 (0.52) | LMNAKDM4ESMN1; SMN2HSP90AA1HTT | |
| SCHEMBL12747782 | 0.75 | KDM4E (0.48) | LMNAKDM4ESMN1; SMN2HSP90AA1HTT | |
| SCHEMBL2008991 | 0.75 | CCR1 (0.48) | LMNAKDM4ESMN1; SMN2HSP90AA1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12410183-B2 | Sars-cov2 main protease inhibitors | GILEAD SCIENCES, INC. (US) | 2025-09-09 | — | — | US | disclosed |
| EP-3351533-B1 | BIARYL DERIVATIVE AND MEDICINE CONTAINING SAME | KAKEN PHARMA CO LTD (JP) | 2025-07-23 | — | — | EP | disclosed |
| EP-4565574-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2025-06-11 | — | — | EP | disclosed |
| US-20250042915-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | GILEAD SCIENCES, INC. | 2025-02-06 | — | — | US | disclosed |
| US-12091420-B2 | SARS-COV2 main protease inhibitors | GILEAD SCIENCES, INC. (US) | 2024-09-17 | — | — | US | disclosed |
| US-20240239807-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | GILEAD SCIENCES, INC. | 2024-07-18 | — | — | US | disclosed |
| US-20240116946-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | GILEAD SCIENCES, INC. | 2024-04-11 | — | — | US | disclosed |
| WO-2024031089-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2024-02-08 | — | — | WO | disclosed |
| WO-2023180189-A1 | MPRO TARGETING ANTIVIRAL COMPOUNDS | EXSCIENTIA AI LIMITED (GB) | 2023-09-28 | — | — | WO | disclosed |
| WO-2023044171-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. (US) | 2023-03-23 | — | — | WO | disclosed |
| US-6610701-B2 | For therapy and prophylaxis of blood coagulation and cardiovascular disorders | MERCK & CO., INC. | 2003-08-26 | — | — | US | disclosed |
| US-20030158218-A1 | Thrombin inhibitors | NANTERMET PHILIPPE G (US) | 2003-08-21 | — | — | US | disclosed |
| US-20020193398-A1 | Thrombin inhibitors | MERCK & CO., INC. | 2002-12-19 | — | — | US | disclosed |
| US-6465482-B2 | ANTIDEPRESSANTS; ANXIOLYTIC AGENTS; SEROTONIN-AFFECTED NERVOUS SYSTEM DISORDERS; ACTING AT THE 5-HT1A AUTORECEPTORS CONCOMMITANTLY WITH 5-HT TRANSPORTERS; ANTISEROTONIN AGENTS; SEROTONIN REUPTAKE INHIBITORS; HT3 RECEPTOR ANTAGONISTS | WYETH | 2002-10-15 | — | — | US | disclosed |
| WO-2002064211-A1 | THROMBIN INHIBITORS | MERCK & CO., INC. (US) | 2002-08-22 | — | — | WO | disclosed |
| US-20020045628-A1 | Arylpiperazinyl-cyclohexyl indole derivatives for the treatment of depression | AMERICAN HOME PRODUCTS CORPORATION (US) | 2002-04-18 | — | — | US | disclosed |
| CN-1336916-A | Arylpiperazinyl-cyclohexyl indole derivatives for the treatment of depression | AMERICAN HOME PROD (US) | 2002-02-20 | — | — | CN | disclosed |
| US-6313126-B1 | FOR THRERAPY OF DISORDERS ASSOCIATED WITH DYSFUNCTION IN SEROTONERGIC NEUROTRANSMISSION, INCLUDING DEPRESSION AND ANXIETY | AMERICAN HOME PRODUCTS CORP | 2001-11-06 | — | — | US | disclosed |
| EP-1147083-A1 | ARYLPIPERAZINYL-CYCLOHEXYL INDOLE DERIVATIVES FOR THE TREATMENT OF DEPRESSION | AMERICAN HOME PRODUCTS CORPORATION (US) | 2001-10-24 | — | — | EP | disclosed |
| WO-2000040554-A1 | ARYLPIPERAZINYL-CYCLOHEXYL INDOLE DERIVATIVES FOR THE TREATMENT OF DEPRESSION | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250042915-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | ACE2, TMPRSS2, ACE | LMNA 3885/4885KDM4E 3744/4885SMN1; SMN2 2647/4885 |
| US-12091420-B2 | SARS-COV2 main protease inhibitors | ACE2, TMPRSS2, ACE | LMNA 3885/4885KDM4E 3744/4885SMN1; SMN2 2647/4885 |
| US-20240116946-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | ACE2, TMPRSS2, ACE | LMNA 3885/4885KDM4E 3744/4885SMN1; SMN2 2647/4885 |
| US-20020045628-A1 | Arylpiperazinyl-cyclohexyl indole derivatives for the treatment of depression | HTR2C, TPH1, TPH2 | LMNA 3470/4885KDM4E 1582/4885SMN1; SMN2 1693/4885 |
| US-12410183-B2 | Sars-cov2 main protease inhibitors | ACE2, TMPRSS2, ACE | LMNA 3885/4885KDM4E 3744/4885SMN1; SMN2 2647/4885 |
| US-20030158218-A1 | Thrombin inhibitors | F2, SERPINC1, TFPI | LMNA 3043/4885KDM4E 4360/4885SMN1; SMN2 4838/4885 |
| US-20240239807-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | ACE2, TMPRSS2, ACE | LMNA 3885/4885KDM4E 3744/4885SMN1; SMN2 2647/4885 |
| US-20020193398-A1 | Thrombin inhibitors | F2, F3, TFPI | LMNA 1368/4885KDM4E 3146/4885SMN1; SMN2 4778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.